Global Diabetic Neuropathy Market Forecast 2029: Size, Share, and Competitive Landscape
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Diabetic Neuropathy Market In The Coming Years?
The market size for diabetic neuropathy has significantly expanded over the past years. It is expected to surge from $5.79 billion in 2024 to $6.21 billion in 2025, marking a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the growth during the historical period include an increase in global diabetes cases, heightened awareness and detection, progress in diabetes care, expanded healthcare spending, investments in research and development, and initiatives aimed at educating patients.
The market size for diabetic neuropathy is poised for robust expansion in the coming years, and is projected to reach a staggering value of $9.15 billion by 2029, reflecting a compound annual growth rate (CAGR) of 10.2%. The anticipated growth during the forecast period can be credited to the progress in neuroimaging, patient-focused care methods, larger clinical trials, consistent increase in diabetes instances, precision healthcare methods, widening of regenerative medicine, and patient advocacy and aid programs. Motivating the forecast period are major trends such as cooperative initiatives in medical studies, digitised health remedies, progresses in diagnostic technology, neuroprotective treatments, personally tailored treatment plans, and implementation of artificial intelligence.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9057&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Diabetic Neuropathy Market?
The increasing incidence of diabetes is predicted to propel the diabetic neuropathy market’s expansion in the future. Diabetes is a chronic ailment in which the body fails to adequately use and manage glucose (a form of sugar). It transpires when the body either doesn’t produce sufficient insulin (a hormone responsible for regulating blood sugar) or doesn’t beneficially use the insulin produced. Diabetic neuropathy refers to a nerve damage type that diabetics can experience, with various nerve damage forms causing different symptoms. Take for example, the IDF Diabetes Atlas report in August 2022, produced by the International Diabetes Federation, a Belgium-based global diabetes society and the umbrella organization for over 230 national diabetes associations, declared that diabetes caused 6.7 million deaths in 2021, equating to one death every five seconds. Presently, 537 million adults (ages 20-79) or 1 in 10 individuals, are living with diabetes. Forecasts suggest that this figure will rise to 643 million by 2030 and 783 million by 2045. Accordingly, the escalating incidence of diabetes is fueling the growth of the diabetic neuropathy market.
Which Sub-Segments Are Driving Growth Within The Diabetic Neuropathy Market?
The diabetic neuropathymarket covered in this report is segmented –
1) By Disorder: Peripheral Neuropathy; Autonomic Neuropathy; Proximal Neuropathy; Focal Neuropathy
2) By Drug Class: Analgesics; Anti-Depressants; Anti-Convulsants; Other Drug Classes
3) By Treatment: Drug Treatment; Radiotherapy; Physiotherapy; Other Treatments
4) By Distribution Channel: Online Distribution; Offline Distribution
5) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyneuropathy
2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy; Gastrointestinal Autonomic Neuropathy; Genitourinary Autonomic Neuropathy
3) By Proximal Neuropathy: Diabetic Amyotrophy; Lumbosacral Plexus Neuropathy
4) By Focal Neuropathy: Cranial Neuropathy; Cervical Radiculopathy; Other Focal Neuropathies
What Current And Upcoming Trends Are Shaping The Diabetic Neuropathy Market?
Leading organizations in the diabetic neuropathy market are developing progressive products like the neuromodulation therapy device to provide better treatment alternatives for those dealing with chronic pain from diabetic neuropathy. These devices offer non-surgical methods by regulating the nerve activity, leading to pain relief, improved nerve function, and promoted healing for those with diabetic nerve damage. For example, Neuralace Medical, Inc., a US based firm offering non-pharmaceutical pain management treatment, acquired FDA approval in January 2024 for their Axon Therapy for Chronic Painful Diabetic Neuropathy. The Axon Therapy device, specifically created to address chronic painful diabetic neuropathy (CPDN), harnesses neuromodulation strategies to alleviate the pain related to diabetic neuropathy. This marks a notable progress in pain management choices for patients dealing with this health issue. This approval highlights the safety and effectiveness of the device and enables Neuralace to proceed with its commercialization, thereby widening the access to efficient treatment services for those afflicted by CPDN.
Which Players Are Shaping The Competitive Landscape Of The Diabetic Neuropathy Market?
Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
How Do Regional Dynamics Influence The Diabetic Neuropathy Market Performance?
North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9057&type=smp
Browse Through More Reports Similar to the Global Diabetic Neuropathy Market 2025, By The Business Research Company
Neurology Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Neurodegenerative Disorder Therapeutic Global Market Report 2025
Neurophysiology Devices And Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
